These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22068367)

  • 1. Successful treatment of toxic epidermal necrolysis/Stevens-Johnson syndrome overlap with human granulocyte colony stimulating factor: a case report.
    Pallesen KA; Robinson S; Toft P; Andersen KE
    Acta Derm Venereol; 2012 Mar; 92(2):212-3. PubMed ID: 22068367
    [No Abstract]   [Full Text] [Related]  

  • 2. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
    Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
    Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Ang CC; Tay YK
    Int J Dermatol; 2011 Dec; 50(12):1570-8. PubMed ID: 22098009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
    Ririe MR; Blaylock RC; Morris SE; Jung JY
    J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer.
    Urosevic-Maiwald M; Harr T; French LE; Dummer R
    Int J Dermatol; 2012 Jul; 51(7):864-7. PubMed ID: 22715836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].
    Molgó M; Carreño N; Hoyos-Bachiloglu R; Andresen M; González S
    Rev Med Chil; 2009 Mar; 137(3):383-9. PubMed ID: 19621180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of granulocyte colony-stimulating factor in the treatment of toxic epidermal necrolysis--experience with 3 patients.
    Mahajan R; Kanwar AJ
    Skinmed; 2013; 11(5):269-71. PubMed ID: 24340465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Sanclemente G; De la Roche CA; Escobar CE; Falabella R
    Int J Dermatol; 1999 Nov; 38(11):878-9. PubMed ID: 10583942
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcome of Stevens Johnson syndrome and toxic epidermal necrolysis treated with corticosteroids.
    Rijal A; Agrawal S
    Indian J Dermatol Venereol Leprol; 2009; 75(6):613-4. PubMed ID: 19915248
    [No Abstract]   [Full Text] [Related]  

  • 11. Case report: psychosis with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    de Rego JA; Goldstein DM
    Hillside J Clin Psychiatry; 1985; 7(2):141-8. PubMed ID: 4077031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and local management at the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.
    Sotozono C; Ueta M; Kinoshita S
    Am J Ophthalmol; 2010 Feb; 149(2):354; author reply 355. PubMed ID: 20103059
    [No Abstract]   [Full Text] [Related]  

  • 13. IVIG for the treatment of toxic epidermal necrolysis.
    Mittmann N; Chan BC; Knowles S; Shear NH
    Skin Therapy Lett; 2007 Feb; 12(1):7-9. PubMed ID: 17361314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced Lyell and Stevens-Johnson syndromes.
    Prescrire Int; 2009 Feb; 18(99):20-2. PubMed ID: 19391288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Considerations on a case of toxic epidermic necrolysis (Lyell's syndrome) with Stevens-Johnson pluriorificial syndrome].
    Cislaghi F; Pagliano Sassi L; Moreno A
    Minerva Pediatr; 1967 Mar; 19(12):540-2. PubMed ID: 5607236
    [No Abstract]   [Full Text] [Related]  

  • 16. Early gynaecological assessment following Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Madhuri TK; Kremer C
    J Obstet Gynaecol; 2010; 30(8):871-2. PubMed ID: 21126137
    [No Abstract]   [Full Text] [Related]  

  • 17. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
    Tan SK; Tay YK
    Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management of severe ocular complications of stevens-johnson syndrome and toxic epidermal necrolysis.
    Sotozono C; Ueta M; Kinoshita S
    Arch Dermatol; 2009 Nov; 145(11):1336-7; author reply 1337-8. PubMed ID: 19917974
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany.
    Rzany B; Mockenhaupt M; Stocker U; Hamouda O; Schöpf E
    Arch Dermatol; 1993 Aug; 129(8):1059. PubMed ID: 8352614
    [No Abstract]   [Full Text] [Related]  

  • 20. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.
    Teo L; Tay YK; Liu TT; Kwok C
    Singapore Med J; 2009 Jan; 50(1):29-33. PubMed ID: 19224081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.